Literature DB >> 24440782

Stratified control of IGF-I expression by hypoxia and stress hormones in osteoblasts.

Thomas L McCarthy1, Zhong Yun2, Joseph A Madri3, Michael Centrella4.   

Abstract

Bone cells respond to the integrated effects of local and systemic regulation. Here we show that hypoxia and the stress hormones PGE2 and glucocorticoid interact in complex ways in osteoblasts, converging on insulin like growth factor I (IGF-I) expression. Whereas hypoxia alone rapidly increased transcription factor HIF activity, it suppressed DNA synthesis, had no significant effects on protein synthesis or alkaline phosphatase activity, and drove discrete changes in a panel of osteoblast mRNAs. Notably, hypoxia increased expression of the acute phase response transcription factor C/EBPδ which can induce IGF-I in response to PGE2, but conversely prevented the stimulatory effect of PGE2 on IGF-I mRNA. However, unlike its effect on C/EBPδ, hypoxia suppressed expression of the obligate osteoblast transcription factor Runx2, which can activate an upstream response element in the IGF-I gene promoter. Hypoxic inhibition of IGF-I and Runx2 were enforced by glucocorticoid, and continued with prolonged exposure. Our studies thus reveal that IGF-I expression is stratified by two critical transcriptional elements in osteoblasts, which are resolved by the individual and combined effects of hypoxic stress and stress hormones. In so doing, hypoxia suppresses Runx2, limits the enhancing influence of PGE2, and interacts with glucocorticoid to reduce IGF-I expression by osteoblasts.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  C/EBP; Glucocorticoid; HIF; PGE2; Runx2

Mesh:

Substances:

Year:  2014        PMID: 24440782      PMCID: PMC4316208          DOI: 10.1016/j.gene.2014.01.011

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  97 in total

1.  Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system.

Authors:  Daniel P Stiehl; Renato Wirthner; Jens Köditz; Patrick Spielmann; Gieri Camenisch; Roland H Wenger
Journal:  J Biol Chem       Date:  2006-06-21       Impact factor: 5.157

Review 2.  Perspectives on RUNX genes: an update.

Authors:  M Michael Cohen
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

3.  Changes in bone morphogenetic protein sensitivity relative to differentiation in fetal rat bone cell cultures.

Authors:  M Centrella; S Casinghino; C Gundberg; T L McCarthy; J Wozney; V Rosen
Journal:  Ann N Y Acad Sci       Date:  1996-06-08       Impact factor: 5.691

4.  Repetitive exposure to TGF-beta suppresses TGF-beta type I receptor expression by differentiated osteoblasts.

Authors:  Kenneth K Kim; Changhua Ji; Weizhong Chang; Rebecca G Wells; Caren M Gundberg; Thomas L McCarthy; Michael Centrella
Journal:  Gene       Date:  2006-05-19       Impact factor: 3.688

5.  Hypoxia regulates PGE(2) release and EP1 receptor expression in osteoblastic cells.

Authors:  Christina M Lee; Damian C Genetos; Zongbing You; Clare E Yellowley
Journal:  J Cell Physiol       Date:  2007-07       Impact factor: 6.384

6.  Adaptive myogenesis under hypoxia.

Authors:  Zhong Yun; Qun Lin; Amato J Giaccia
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  Runx2 in normal tissues and cancer cells: A developing story.

Authors:  Karen Blyth; Francois Vaillant; Alma Jenkins; Laura McDonald; Marie Anne Pringle; Camille Huser; Torsten Stein; James Neil; Ewan R Cameron
Journal:  Blood Cells Mol Dis       Date:  2010-06-26       Impact factor: 3.039

8.  Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E2 in osteoblasts.

Authors:  M J Thomas; Y Umayahara; H Shu; M Centrella; P Rotwein; T L McCarthy
Journal:  J Biol Chem       Date:  1996-09-06       Impact factor: 5.157

9.  Regulation of insulin-like growth factor I transcription by cyclic adenosine 3',5'-monophosphate (cAMP) in fetal rat bone cells through an element within exon 1: protein kinase A-dependent control without a consensus AMP response element.

Authors:  T L McCarthy; M J Thomas; M Centrella; P Rotwein
Journal:  Endocrinology       Date:  1995-09       Impact factor: 4.736

Review 10.  Pathogenesis of retinopathy of prematurity.

Authors:  Lois E H Smith
Journal:  Growth Horm IGF Res       Date:  2004-06       Impact factor: 2.372

View more
  6 in total

Review 1.  Skeletal effects of growth hormone and insulin-like growth factor-I therapy.

Authors:  Richard C Lindsey; Subburaman Mohan
Journal:  Mol Cell Endocrinol       Date:  2015-09-25       Impact factor: 4.102

2.  Biological roles of CCAAT/Enhancer-binding protein delta during inflammation.

Authors:  Chiung-Yuan Ko; Wen-Chang Chang; Ju-Ming Wang
Journal:  J Biomed Sci       Date:  2015-01-16       Impact factor: 8.410

3.  Intermittent Compressive Stress Enhanced Insulin-Like Growth Factor-1 Expression in Human Periodontal Ligament Cells.

Authors:  Jittima Pumklin; Jeeranan Manokawinchoke; Kanokporn Bhalang; Prasit Pavasant
Journal:  Int J Cell Biol       Date:  2015-05-28

4.  Inhibition of PGE2 in Subchondral Bone Attenuates Osteoarthritis.

Authors:  Qi Sun; Yuanzhen Zhang; Yilan Ding; Wenqing Xie; Hengzhen Li; Shaohua Li; Yusheng Li; Ming Cai
Journal:  Cells       Date:  2022-09-05       Impact factor: 7.666

5.  Combination of Cardiac Progenitor Cells From the Right Atrium and Left Ventricle Exhibits Synergistic Paracrine Effects In Vitro.

Authors:  Ryan McQuaig; Parul Dixit; Atsushi Yamauchi; Isabelle Van Hout; Jayanthi Bellae Papannarao; Richard Bunton; Dominic Parry; Philip Davis; Rajesh Katare
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

Review 6.  Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors.

Authors:  Aldona Kasprzak; Witold Szaflarski
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.